Home
About
Pricing
Log In

What are you looking for?

Home
Pricing
Back
Compare AU

Compare VESG vs. CURE

Compare shares and ETFs on the ASX that you can trade on Pearler.

Vanguard Ethically Conscious International Shares Index ETF

ASX

Buy

Buy

S&P US Biotech

ASX

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Vanguard Ethically Conscious International Shares Index ETF (VESG) and the S&P US Biotech (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

VESG

CURE

Popularity

Medium

Low

Pearlers invested

2,830

70

Median incremental investment

$990.50

$678.72

Median investment frequency

Monthly

Monthly

Median total investment

$3,395.32

$2,063.43

Average age group

26 - 35

> 35

Key Summary

VESG

CURE

Strategy

VESG seeks to track the performance of the FTSE Developed ex-Australia Choice Index (with dividends reinvested) before considering any additional fees, expenses, and taxes.

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Top 3 holdings

Apple Inc. (5.54 %)

Microsoft Corp. (4.67 %)

Amazon.com Inc. (2.10 %)

Travere Therapeutics Inc Ordinary Shares (1.79 %)

Revolution Medicines Inc Ordinary Shares (1.78 %)

Alkermes PLC (1.71 %)

Top 3 industries

Information Technology (26.14 %)

Health Care (16.64 %)

Financials (15.14 %)

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (73.05 %)

Japan (6.22 %)

Switzerland (2.78 %)

United States (96.62 %)

United Kingdom of Great Britain and Northern Ireland (1.35 %)

Switzerland (1.13 %)

Management fee

0.18 %

0.45 %

Key Summary

VESG

CURE

Issuer

Vanguard

Global X

Tracking index

FTSE Developed ex Australia Choice Index - AUD

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0.18 %

0.45 %

Price

$117.08

$63.49

Size

N/A

$40.308 million

10Y return

N/A

N/A

Annual distribution yield (5Y)

1.63 %

5.08 %

Market

ASX

ASX

First listed date

13/09/2018

12/11/2018

Purchase fee

$6.50

$6.50

Community Stats

VESG

CURE

Popularity

Medium

Low

Pearlers invested

2,830

70

Median incremental investment

$990.50

$678.72

Median investment frequency

Monthly

Monthly

Median total investment

$3,395.32

$2,063.43

Average age group

26 - 35

> 35

Pros and Cons

VESG

CURE

Pros

  • Higher exposure to AU market

  • Lower management fee

  • Higher price growth

  • Higher exposure to US market

  • Higher distribution yield

Cons

  • Lower exposure to US market

  • Lower distribution yield

  • Lower exposure to AU market

  • Higher management fee

  • Lower price growth

VESG

CURE

Higher exposure to AU market

Lower exposure to AU market

Lower exposure to US market

Higher exposure to US market

Lower management fee

Higher management fee

Higher price growth

Lower price growth

Lower distribution yield

Higher distribution yield